Promoting apoptosis as a strategy for cancer drug discovery

Nature Reviews Cancer

Volumn 5, Issue 11, 2005, Pages 876-885

  Fesik, Stephen W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; CASPASE 8; CHELERYTHRINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEXAMETHASONE; FLUDARABINE; GOSSYPOL; I KAPPA B KINASE INHIBITOR; IMIDAZOLINE DERIVATIVE; IPI 194; IPI 983L; IRINOTECAN; ISOSORBIDE; OBLIMERSEN; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53; RECEPTOR ANTIBODY; SPC 2966; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; YC 137;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER REGRESSION; CELL KILLING; CELL MEMBRANE PERMEABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; CYTOTOXICITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; GLIOMA; HUMAN; INTERNALIZATION; LUNG CANCER; MELANOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28544443984     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1736     Document Type: Review

References (145)

1. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462 (1995).
2. Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 (2004).
3. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
4. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810-816 (2000).
5. Nagata, S. Apoptosis by death factor. Cell 88, 355-365 (1997).
6. Budihardjo, I., Oliver, H., Lutter, M., Luo, X. & Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15, 269-290 (1999).
7. Baell, J. B. & Huang, D. C. S. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol. 64, 851-863 (2002).
8. Deveraux, Q. L., Takahashi, R., Salvesen, G. S. & Reed, J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388, 300-304 (1997).
9. Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42 (2000).
10. Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53 (2000).
11. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 3, 102-109 (2003).
12. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Rev. Cancer 2, 420-421 (2002).
13. Hymowitz, S. G. et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4, 563-571 (1999).
14. Mongkolsapaya, J. et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotis initiation. Nature Struct. Biol. 6, 1048-1053 (1999).
15. Cha, S. S. et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J. Biol. Chem. 275, 31171-31177 (2000).
16. Kelley, S. K. & Ashkenazi, A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4, 333-339 (2004). A comprehensive review on targeting TRAIL receptors.
17. Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891-4898 (2001).
18. Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med. 7, 954-960 (2001).
19. Takeda, K. et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437-448 (2004).
20. Presta, L. G. Engineering antibodies for therapy. Curr. Pharm. Biotechnol. 3, 237-256 (2002).
21. Shankar, S., Chen, X. & Srivastava, R. K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62, 165-186 (2005).
22. Inoue et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11, S193-S206 (2004).
23. Naka, T. et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62, 5800-5806 (2002).
24. Pollack, I. F., Erff, M. & Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res. 7, 1362-1369 (2001).
25. Jin, H. et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 64, 4900-4905 (2004).
26. Ray, S. & Almasan, A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63, 4713-4723 (2003).
27. Mitsiades, C. S. et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795-804 (2001).
28. Chinnaiyan, A. M. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl Acad. Sci USA 97, 1754-1759 (2000).
29. Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162 (1999).
30. Kelley, S. K. et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299, 31-38 (2001).
31. LeBlanc, H. N. & Ashkenazi, A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differen. 10, 66-75 (2003).
32. Jin, Z., McDonald III, E. R., Dicker, D. T. & El-Deiry, W. S. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279, 35829-35839 (2004).
33. Kazhdan, I. & Marciniak, R. A. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Gene Ther. 11, 691-698 (2004).
34. Chawla-Sarkar, M. et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11, 915-923 (2004).
35. Fulda, S., Wick, W., Weller, M. & Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Med. 8, 808-815 (2002).
36. LeBlanc, H. et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nature Med. 8, 274-281 (2002).
37. Deng, Y., Lin, Y. & Wu, X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16, 33-45 (2002).
38. Ravi, R. & Bedi, A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-xL. Cancer Res. 62, 1583-1587 (2002).
39. Kelekar, A. & Thompson, C. B. Bcl-2 family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 8, 324-330 (1998).
40. Huang, D. C. & Strasser, A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 103, 839-842 (2000).
41. Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730 (2001).
42. Petros, A. M., Olejniczak, E. T. & Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83-94 (2004).
43. Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983-986 (1997). First structure that defined pro- and anti-apoptotic BCL2 family members interacting with one another.
44. Petros, A. M. et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 9, 2528-2534 (2000).
45. Kirkin, V., Joos, S. & Zornig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644, 229-249 (2004).
46. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097-1099 (1984).
47. Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E. & Croce, C. M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229, 1390-1393 (1985).
48. Gaulard, P. et al. Expression of the bcl-2 gene product in follicular lymphoma. Am. J. Pathol. 140, 1089-1095 (1992).
49. Ben-Ezra, J. M., Kornstein, M. J., Grimes, M. M. & Krysal, G. Small cell carcinomas of the lung express the Bcl-2 protein. Am. J. Pathol. 145, 1036-1040 (1994).
50. Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H. & Tateishi, R. High prevalence of bcl-2 oncoprotien expression in small cell lung cancer. Anticancer Res. 15, 503-505 (1995).
51. Schena, M. et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79, 2981-2989 (1992).
52. Harada, N. et al. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 12, 1817-1820 (1998).
53. Leiter, U., Schmid, R. M., Kaskel, P., Peter, R. U. & Krahn, G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch. Dermatol. Res. 292, 225-232 (2000).
54. Matsushima, H. et al. Combined analysis with Bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol. 158, 2278-2283 (1997).
55. Keshgegian, A. A., Johnston, E. & Cnaan, A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am. J. Clin. Pathol. 110, 443-449 (1998).
56. Mano, Y. et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur. J. Cancer 35, 1214-1219 (1999).
57. Rajkumar, T. et al. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur. J. Gynaecol. Oncol. 19, 556-560 (1998).
58. Ye, D. et al. Bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J. Urol. 160, 2025-2028 (1998).
59. Nakata, B. et al. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology 55, 543-547 (1998).
60. Fries, H. et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann. Surg. 228, 780-787 (1998).
61. Lipponen, P. et al. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J. Pathol. 177, 49-55 (1995).
62. Le, M. G. et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int. J. Cancer 84, 562-567 (1999).
63. Nakopoulou, L. et al. bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining. Histopathology 34, 310-319 (1999).
64. Sinicrope, F. A., Hart, J., Michelassi, F. & Lee, J. J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin. Cancer Res. 1, 1103-1110 (1995).
65. Ofner, D. et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer 72, 981-985 (1995).
66. Baretton, G. B. et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77, 255-264 (1996).
67. Leahy D. T., Mulcahy, H. E., O'Donoghue, D. P. & Parfrey, N. A. bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology 35, 360-367 (1999).
68. Ohmori, T. et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun. 192, 30-36 (1993).
69. Minn, A. J., Rudin, C. M., Boise, L. H. & Thompson, C. B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86, 1903-1910 (1995).
70. Harima, Y. et al. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J. Cancer Res. Clin. Oncol. 124, 503-510 (1998).
71. Mackey, T. J., Borkowski, A., Amin, P., Jacobs, S. C. & Kyprianou, N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52, 1085-1090 (1998).
72. L as a cancer target
73. Klasa, R. J., Gillum, A. M., Klem, R. E. & Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Devel. 12, 193-213 (2002). Summary of the use of BCL2 antisense in anticancer treatment.
74. Cummings, J., Ward, T. H., Ranson, M. & Dive, C. Apoptosis pathway-targeted drugs - from the bench to the clinic. Biochim. Biophys. Acta 1705, 53-66 (2004).
75. Gleave, M. E. & Monia, B. P. Antisense therapy for cancer. Nature Rev. Cancer 5, 468-479 (2005).
76. Frantz, S. Lessons learnt from Genasense's failure. Nature Rev. Drug Discov. 3, 542-543 (2004).
77. Agrawal, S. & Kandimalla, E. R. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets 1, 197-209 (2001).
78. Zangemeister-Wittke, U. et al. A nova bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-XL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6, 2547-2555 (2000).
79. Holinger, E. P., Chittenden, T. & Lutz, R. J. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem. 274, 13298-13304 (1999).
80. Wang, J. L. et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 60, 1498-1505 (2000).
81. Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004).
82. Kutzki, O. et al. Development of a potent Bcl-xL antagonist based on α-helix mimicry. J. Am. Chem. Soc. 124, 11838-11839 (2002).
83. Tzung, S. P. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol. 3, 183-191 (2001).
84. Chan, S. L. et al. Identification of chelerythrine as an inhibitor of BclXL function. J. Biol. Chem. 278, 20453-20456 (2003).
85. Real, P. J. et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res. 64, 7947-7953 (2004).
86. Wang, J. L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124-7129 (2000).
87. Kitada, S. et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 46, 4259-4264 (2003).
88. Mohammad, R. M. et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther. 4, 13-21 (2005).
89. Oliver, C. L. et al. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2 and Bcl-X(L)-mediated apoptosis resistance. Mol. Cancer Ther. 4, 23-31 (2005).
90. Degterev, A. et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nature Cell Biol. 3, 173-182 (2001).
91. Enyedy, I. J. et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 44, 4313-4324 (2001).
92. Becattini, B. et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-xL. Chem. Biol. 11, 389-395 (2004).
93. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005). Discovery of the most potent BCL2-family inhibitor to date.
94. Sun, C. et al. NMR structure and mutagenesis of the inhibitor-of- apoptosis protein XIAP. Nature 401, 818-822 (1999).
95. Takahashi, R. et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273, 7787-7790 (1998).
96. Riedl, S. J. et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 104, 791-800 (2001).
97. Sun, C. et al. NMR structure and mutagenesis of the third bir domain of the inhibitor of apoptosis protein XIAP. J. Biol. Chem. 275, 33777-33781 (2000).
98. Shiozaki, E. N. et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11, 519-527 (2003).
99. Liu, Z. et al. Structural basis for binding of smac/DIABLO to the XIAP bir3 domain. Nature 408, 1004-1008 (2000). This reference, with reference 100, describes the structure of the SMAC-XIAP-BIR3 complex used in the design of XIAP antagonists.
100. Wu, G. et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 28, 1008-1012 (2000).
101. LaCasse, E. C., Baird, S., Korneluk, R. G. & MacKenzie, A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247-3259 (1998).
102. Hu, Y. et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer c in vitro and in vivo. Clin. Cancer Res. 9, 2826-2836 (2003).
103. Arnt, C. R., Chiorean, M. V., Heldebrant, M. P. Gores, G. J. & Kaufmann, S. H. Synthetic smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277, 44236-44243 (2002).
104. Yang, L. et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated smac peptide. Cancer Res. 63, 831-837 (2003).
105. Sun, H. et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J. Med. Chem. 47, 4147-1150 (2004).
106. Sun, H. et al. Structure-based design of potent, conformationally constrained Smac mimetics. J. Am. Chem. Soc. 126, 16686-16687 (2004).
107. Sun, H. et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg. Med. Chem. Lett. 15, 793-797 (2005).
108. Oost, T. et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47, 4417-4426 (2004).
109. Wu, T. Y. H., Wagner, K. W., Bursulaya, B., Schultz, P. G. & Deveraux, Q. L. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem. Biol. 10, 759-767 (2003).
110. Nikolovska-Coleska, Z. et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47, 2430-2440 (2004).
111. Li, L. et al. A small molecule smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 305, 1471-1474 (2004).
112. Park, C. et al. Non-peptidic small molecule inhibitors of XIAP. Bioorg. Med. Chem. 15, 771-775 (2005).
113. Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25-35 (2004).
114. Ambrosini, G., Adida, C. & Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917-921 (1997). The first report of survivin.
115. Altieri, D. C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581-8589 (2003).
116. Olie, R. A. et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60, 2805-2809 (2000).
117. Grossman, D., Kim, P. J., Schechner, J. S. & Altieri, D. C. Inhibition of melanoma tumor growth in vivo by survivin target. Proc. Natl Acad. Sci. USA 98, 635-640 (2001).
118. Momand, J., Wu, H. H. & Dasgupta, G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene 242, 15-29 (2000).
119. Lane, D. P. & Lain, S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 4 (Suppl.), 38-42 (2002).
120. Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996). Structure of the p53-MDM2 complex used in the design of MDM2 inhibitors.
121. Bottger, A. et al. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269, 744-756 (1997).
122. Stoll, R. et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochem. 2, 336-344 (2001).
123. Zhao, J. et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 2, 69-77 (2002).
124. Duncan, S. J. et al. Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Med. Chem. Soc. 123, 554-560 (2001).
125. Galatin, P. S. & Abraham, D. J. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. 47, 4163-4165 (2004).
126. Parks D. J. et al. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 15, 765-770 (2005).
127. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004). Discovery of the most potent MDM2 inhibitor to date.
128. Workman, P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem. Soc. Trans. 32, 393-396 (2004).
129. Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241 (1997).
130. del Paso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689 (1997).
131. Blume-Jensen, P., Janknecht, R. & Hunter, T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8, 779-782 (1998).
132. Kim, A. H., Khursigara, G., Sun, X., Franke, T. F. & Chao, M. V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase Mol. Cell. Biol. 21, 893-901 (2001).
133. Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857-868 (1999).
134. Kops, G. J. & Burgering, B. M. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J. Mol. Med. 77, 656-665 (1999).
135. Kops, G. J. et al. Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 398, 630-634 (1999).
136. Gelfanov, V. M. et al. Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor κB-mediated antiapoptosis involving c-IAP2. Blood 98, 2508-2517 (2001).
137. Trencia, A. et al. Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol. Cell. Biol. 23, 4511-4521 (2003).
138. Mitsiades, C. S., Mitsiades, N. & Koutsilieris, M. The akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets 4, 235-256 (2004).
139. Lu, Y., Wang, H. & Mills, G. B. Targeting PI3K-akt pathway for cancer therapy. Rev. Clin. Exp. Hematol. 7, 205-228 (2003).
140. Luo, Y. et al. Potent and selective inhibitors of akt kinases slow the progression of tumors in vivo. Mol. Cancer Therap. 4, 977-986 (2005).
141. Rowinsky, E. K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16, 564-575 (2004).
142. Adams, J. The proteasome: a suitable antineoplastic target. Nature Rev. Cancer 4, 349-360 (2004).
143. Fribley, A., Zeng, Q. & Wang, C. Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinomous cells. Mol. Cell. Biol. 24, 9696-9704 (2004).
144. Burke, J. R. Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr. Opin. Drug Discov. Devel. 6, 720-728 (2003).
145. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 88, 1052-1061 (1996).